4.12 Oligonucleotide inhibitors

Inotersen
  • Solution for injection in pre-filled syringes 284mg in 1.5ml

Notes

  1. NICE HST9: Inotersen (Tegsedi) is recommended as an option for treating stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (May 2019)

Transthyretin stabilisers

Patisiran sodium
  • Concentrate for solution for infusion vials 10mg in 5ml

Notes

  1. NICE HST10: Patisiran (Onpattro) is recommended as an option for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy (August 2019)
Tafamidis
  • NICE TA696: Tafamidis (Vyndaqel) is not recommended, within its marketing authorisation, for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR‑CM) in adults (May 2021)
Last updated: 28-10-2019

 

Home > Formulary > Chapters > 4. Central Nervous System > 4.12 Oligonucleotide inhibitors

 

  • First line
  • Second line
  • Specialist
  • Hospital